Barclays Initiates ABIVAX Société (ABVX) With Overweight Rating

​ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the Hot Growth Stocks to Invest in Now. On October 13, Etzer Darout from Barclays initiated ABIVAX Société Anonyme (NASDAQ:ABVX) with an Overweight rating and a $142 price target.

​Analysts noted that they initiated coverage on eight companies in the inflammation, immunology, oncology, and rare disease sectors. He elaborated that while investment in small and mid-cap biotechnology stocks has binary risks. However, investments based on the prior clinical data and other de-risked mechanisms present a favorable risk/reward situation that presents significant upside.

​Moreover, the firm also believes that the market is currently rewarding new mechanisms and treatments that have the potential to improve dosing and compliance.

​In addition to Barclays, earlier on October 10, Yatin Suneja from Guggenheim reiterated a Buy rating on ABIVAX Société Anonyme (NASDAQ:ABVX) with a price target of $150.

​ABIVAX Société Anonyme (NASDAQ:ABVX) is a clinical-stage biotechnology company that develops antiviral compounds and therapeutic vaccines for severe infectious diseases.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.